“Testosterone therapy is safe and worth it for most men with low testosterone.”
For men with symptoms and repeatedly low morning levels, testosterone can ease some symptoms, and a large trial found no rise in heart attacks or strokes.
If you have symptoms and repeat morning tests confirm low testosterone, treatment can be worth it, and a large trial found it did not raise the risk of heart attack or stroke. If you have one low result, only vague tiredness, or want children soon, testosterone is usually not the right choice.
Repeat an early-morning fasting testosterone test with a reliable assay, evaluate the cause, and discuss fertility and monitoring before starting therapy.
Safety note: Testosterone suppresses sperm production, can raise hematocrit and requires monitoring. In TRAVERSE, major cardiovascular events were not increased, but atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
Talk to a healthcare professional if: you are thinking about testosterone, especially if you want to father a child, or you have a high red blood cell count, untreated severe sleep apnea, prostate or breast cancer concerns, severe urinary symptoms, a heart attack or stroke in the past 6 months, uncontrolled heart failure or a clotting disorder.
Strong confidence for the conditional conclusion. Guidelines require symptoms plus consistently low morning testosterone, and a large randomized trial was reassuring for major cardiovascular events in appropriately selected men. Benefits, fertility effects, monitoring and longer-term uncertainties still vary by person.
For men with symptoms and repeatedly low morning levels, testosterone can ease some symptoms, and a large trial found no rise in heart attacks or strokes. One low test or tiredness alone is not enough, and whether treatment is worthwhile depends on the cause, symptoms, fertility goals, contraindications and response.
The strongest safety trial followed men for about three years and was designed around major cardiovascular events. It does not prove lifelong safety or justify use for normal aging, bodybuilding or an unconfirmed laboratory result.
- Lincoff AM, Bhasin S, Flevaris P, et al.; TRAVERSE Study Investigators. Cardiovascular safety of testosterone-replacement therapy. New England Journal of Medicine. 2023;389(2):107-117. doi:10.1056/NEJMoa2215025. PMID:37326322
- Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744. doi:10.1210/jc.2018-00229. PMID:29562364